摘要
随着生物质谱技术的发展和蛋白质组学的成熟,人们已经能够对疾病发生、发展过程的蛋白质组进行定性和定量分析,筛选出可用于疾病诊断、分型、疗效监测、判断预后等作用的生物标志物。甲状腺乳头状癌是最常见的甲状腺癌病理类型,目前其存在发病机制不明、现有金标准诊断手段(细针穿刺)有创且其精准度不高、针对复杂难治型患者(如碘抵抗患者)术后放化疗效果不佳等问题。因而,应用基于生物质谱技术的蛋白质组学筛选甲状腺癌血浆、尿液等样本中的生物标志物,对于该疾病的无创或微创诊断具有推动作用。
With the development of biomass spectrometry and the maturity of proteomics,people have been able to conduct qualitative and quantitative analysis of the proteome during the occurrence and development of diseases,and screen out biomarkers that can be used for disease diagnosis,typing,efficacy monitoring,prognosis judgment and other functions.As the most common pathological type of thyroid cancer,thyroid papillary carcinoma is faced with many problems,such as unclear pathogenesis,invasive and inaccurate existing gold standard diagnostic means(fine needle puncture),and poor postoperative radiotherapy and chemotherapy effects on patients with complex and refractory types(such as those with iodine resistance).Therefore,the application of proteomics based on biomass spectrometry to screen biomarkers in plasma,urine and other samples of thyroid cancer can promote the non-invasive or minimally invasive diagnosis of the disease.
作者
赵婉君
张勇
付琳茹
杨浩
朱精强
ZHAO Wanjun;ZHANG Yong;FU Linru;YANG Hao;ZHU Jingqiang(Department of Thyroid Surgery,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Transplantation Immunology/West China Hospital-Washington University Center for Mitochondria and Metabolism,West China Hospital,Sichuan University,Chengdu 610041,China;West China School of Medicine,Sichuan University,Chengdu 610041,China)
出处
《医学综述》
2019年第15期3014-3018,共5页
Medical Recapitulate
基金
国家自然科学基金(81871475)
四川大学华西医院专职博士后研发基金(2018HXBH062,2018HXBH074)
